Adrenocortical tumors: Recent advances in basic concepts and clinical management

Annals of Internal Medicine

Volumn 130, Issue 9, 1999, Pages 759-771

  Bornstein, Stefan R ^a   Stratakis, Constantine A ^a   Chrousos, George P ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENAL CORTEX TUMOR; ALGORITHM; CANCER GENETICS; CELL COMMUNICATION; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; HISTOPATHOLOGY; HUMAN; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TUMOR DIAGNOSIS;

EID: 0033522431     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-9-199905040-00017     Document Type: Conference Paper

References (143)

1. Latronico AC, Chrousos GP. Extensive personal experience: adrenocortical tumors. J Clin Endocrinol Metab. 1997;82:1317-24.
2. Ross NS, Aron DC. Current hormonal evaluation of the patient with an incidentally discovered adrenal mass. N Engl J Med. 1990;323:1401-5.
3. Adler M, Robbins R. Recent advances in the management of adrenal incidentalomas. Trends Endocrinol and Metab. 1998;9:190-4.
4. Copeland PM. The incidentally discovered adrenal mass. Ann Intern Med. 1983;98:940-5.
5. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev. 1995;16:460-84.
6. Chrousos GP. Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann N Y Acad Sci. 1998;851:311-35.
7. Goldstein DS. Stress response patterns. In: Goldstein DS, ed. Stress, Catecholamines, and Cardiovascular Disease. New York: Oxford Univ Pr; 1995: 287-328.
8. Ehrhart-Bornstein M, Hinson JP, Bornstein SR, Scherbaum WA, Vinson GP. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis. Endocr Rev. 1998;19:101-43.
9. Bornstein SR, Vaudry H. Paracrine and neuroendocrine regulation of the adrenal gland - basic and clinical aspects [Editorial]. Horm Metab Res. 1998; 30:292-6.
10. Pignatelli D, Magalhaes MM, Magalhaes MC. Direct effects of stress on adrenocortical function. Horm Metab Res. 1998;30:464-74.
11. Engeland WC. Functional innervation of the adrenal cortex by the splanchnic nerve. Horm Metab Res. 1998;30:311-4.
12. McDonald TJ, Nathanielsz PW. The involvement of innervation in the regulation of fetal adrenal steroidogenesis. Horm Metab Res. 1998;30:297-302.
13. Vinson GP, Pudney JA, Whitehouse BJ. The mammalian adrenal circulation and the relationship between adrenal blood flow and steroidogenesis. J Endocrinol. 1985;105:285-94.
14. Wolkersdörfer GW, Bornstein SR. Tissue remodelling in the adrenal gland. Biochem Pharmacol 1998;56:163-71.
15. Bornstein SR, Ehrhart-Bornstein M, Usadel H, Böckmann M, Scherbaum WA. Morphological evidence for a close interaction of chromaffin cells with cortical cells within the adrenal gland. Cell Tissue Res. 1991;265:1-9.
16. Bornstein SR, González-Hernández JA, Ehrhart-Bornstein M, Adler G, Scherbaum WA. Intimate contact of chromaffin and cortical cells within the human adrenal gland forms the cellular basis for important intraadrenal interactions. J Clin Endocrinol Metab. 1994;78:225-32.
17. Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA. Pfeiffer EF, Holst JJ. Effects of splanchnic nerve stimulation on the adrenal cortex may be mediated by chromaffin cells in a paracrine manner. Endocrinology. 1990; 127:900-6.
18. Bornstein SR, Ehrhart-Bornstein M. Ultrastructural evidence for a paracrine regulation of the rat adrenal cortex mediated by the local release of catecholamines from chromaffin cells. Endocrinology. 1992;131:3126-8.
19. Nussdorfer GG. Paracrine control of adrenal cortical function by medullary chromaffin cells. Pharmacol Rev. 1996;48:495-530.
20. Baird A, Bohlen A. Fibroblast growth factors. In: Sporn MB, Roberts AB, eds. Peptide Growth Factors and Their Receptors, v 1. Berlin: Springer-Verlag; 1990:369-418.
21. Rechler MM, Nissley SP. Insulin-like growth factors. In: Sporn MB, Roberts AB, eds. Peptide Growth Factors and Their Receptors, v 1. Berlin: Springer-Verlag; 1990:263-367.
22. Roberts AB, Sporn MB. The transforming growth factors-β. In: Sporn MB, Roberts AB, eds. Peptide Growth Factors and Their Receptors, v 1. Berlin: Springer-Verlag; 1990:419-72.
23. Feige JJ, Baird A. Growth factor regulation of adrenal cortex growth and function. Prog Growth Factor Res. 1991;3:103-13.
24. Voutilainen R. Adrenocortical cells are the site of secretion and action of insulin-like growth factors and TNF-alpha. Horm Metab Res. 1998;30:432-5.
25. Panayotou G, Waterfield MD. The assembly of signalling complexes by receptor tyrosine kinases. Bioessays. 1993;15:171-7.
26. LeRoith D, Sampson PC, Roberts CT Jr. How does the mitogenic insulin-like growth-factor I receptor differ from the metabolic insulin receptor? Horm Res. 1994;41(Suppl 2):74-8.
27. Lee J, Pilch PF. The insulin receptor: structure, function, and signaling. Am J Physiol. 1994;266(2 pt 1):C319-34.
28. Avruch J, Zhang X, Kyriakis JM. Raf meets Ras: completing the framework of a signal transduction pathway. Trends Biochem Sci. 1994;19:279-83.
29. Ehrhart-Bornstein M, Bornstein SR, Scherbaum WA. Sympathoadrenal system and immune system in the regulation of adrenocortical function. Eur J Endocrinol. 1996;135:19-26.
30. Marx C, Ehrhart-Bornstein M, Scherbaum WA, Bornstein SR. Regulation of adrenocortical function by cytokines - relevance for immune-endocrine interaction. Horm Metab Res. 1998;30:416-20.
31. Roh MS, Drazenovich KA, Barbose JJ, Dinarello CA, Cobb CF. Direct stimulation of the adrenal cortex by interleukin-1. Surgery. 1987;102:140-6.
32. Päth G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J Clin Endocrinol Metab. 1997;82:2343-9.
33. Päth G, Bornstein SR, Späth-Schwalbe E, Scherbaum WA. Direct effects of interleukin-6 on human adrenal cells. Endocr Res. 1996;22:867-73.
34. Jäättelä M, Ilvesmäki V, Voutilainen R, Stenman UH, Saksela E. Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. Endocrinology. 1991;128:623-9.
35. Ilvesmäki V, Jäättelä M, Saksela E, Voutilainen R. Tumor necrosis factor-alpha and interferon-gamma inhibit insulin-like growth factor II gene expression in human fetal adrenal cell cultures. Mol Cell Endocrinol. 1993; 91:59-65.
36. Khoury EL, Greenspan JS, Greenspan FS. Adrenocortical cells of the zona reticularis normally express HLA-DR antigenic determinants. Am J Pathol. 1987;127:580-91.
37. Marx C, Bornstein SR, Wolkersdörfer GW, Peter M, Sippell WG, Scherbaum WA. Relevance of major histocompatibility complex class II expression as a hallmark for the cellular differentiation in the human adrenal cortex. J Clin Endocrinol Metab. 1997;82:3136-40.
38. Marx C, Wolkersdörfer GW, Brown JW, Scherbaum WA, Bornstein SR. MHC class II expression - a new tool to assess dignity in adrenocortical tumours. J Clin Endocrinol Metab. 1996;81:4488-91.
39. Ilvesmaki V, Kahri AI, Miettinen PJ, Voutilainen R. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors; high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 1993;77: 852-8.
40. Liu J, Kahri AI, Heikkila P, Ilvesmaki V, Voutilainen R. H19 and insulin-like growth factor-II gene expression in adrenal tumors and cultural adrenal cells. J Clin Endocrinol Metab. 1995;80:492-6.
41. Sasano H, Suzuki T, Shizawa S, Kato K, Nagura H. Transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor expression in normal and diseased human adrenal cortex by immunohistochemistry and in situ hybridization. Mod Pathol. 1994;7:741-6.
42. Ehrhart-Bornstein M, Bornstein SR. Regulation of adrenocortical function by the sympathoadrenal system: physiology and pathology. In: Margioris AN, Chrousos GP, eds. Adrenal Disorders. Humana Pr; [In press].
43. Lacroix A, Tremblay J, Touyz RM, Deng LY, Lariviere R, Cusson JR, et al. Abnormal adrenal and vascular responses to vasopressin mediated by a V1-vasopressin receptor in a patient with adrenocorticotropin-independent macronodular adrenal hyperplasia, Cushing's syndrome, and orthostatic hypotension. J Clin Endocrinol Metab. 1997;82:2414-22.
44. Lacroix A, Bolté E, Tremblay J, Dupré J, Poitras P, Fournier H, et al. Gastric inhibitory polypeptide-dependent cortisol hypersecretion - a new cause of Cushing's syndrome. N Engl J Med. 1992;327:974-80.
45. Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, et al. Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med. 1992;327: 981-6.
46. Haidan A, Hilbers U, Bornstein SR, Ehrhart-Bornstein M. Human adrenocortical NCI-H295 cells express VIP receptors. Steroidogenic effect of vasoactive intestinal peptide (VIP). Peptides. 1998;19:1511-7.
47. Leinonen P, Ranta T, Siegberg R, Pelkonen R, Heikkila T, Kahri A. Testosterone-secreting virilizing adrenal adenoma with human chorionic gonadotrophin receptors and 21-hydroxylase deficiency. Clin Endocrinol (Oxf). 1991;34:31-5.
48. Lacroix A, Tremblay J, Rousseau G, Bouvier M. Hamet P. Propranolol therapy for ectopic β-adrenergic receptors in adrenal Cushing's syndrome. N Engl J Med. 1997;337:1429-34.
49. N'Diaye N, Tremblay J, Hamet P, Lacroix A. Hormone receptor abnormalities in adrenal Cushing's syndrome. Horm Metab Res. 1998;30:440-6.
50. Willenberg HS, Stratakis CA, Marx C, Ehrhart-Bornstein M, Chrousos GP, Bornstein SR. Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing's syndrome. N Engl J Med. 1998;339: 27-31.
51. Whitcomb RW, Linehan WM, Wahl LM, Knazek RA. Monocytes stimulate cortisol production by cultured human adrenocortical cells. J Clin Endocrinol Metab. 1988;66:33-8.
52. Wegienka LC Komarmy LE, Wuepper KD, Forsham PH. Cushing's syndrome with adrenal medullary insufficiency and adrenal autoantibodies. Lancet. 1966;1:741-3.
53. Andrada JA, Murray FT, Andrada EC, Ezrin C. Cushing's syndrome and autoimmunily. Arch Pathol Lab Med. 1979;103:244-6.
54. Reincke M, Mora P, Beuschlein F, Arlt W, Chrousos GP, Allolio B. Deletion of the adrenocorticotropin receptor gene in human adrenocortical tumors: implications for tumorigenesis. J Clin Endocrinol Metab. 1997;82: 3054-8.
55. Latronico AC, Reincke M, Mendonca BB, Arai K, Mora P, Allolio B, et al. No evidence for oncogenic mutations in the adrenocorticotropin receptor gene in human adrenocortical neoplasms. J Clin Endocrinol Metab. 1995; 80:875-7.
56. Reincke M, Karl M, Travis W, Chrousos GP. No evidence for oncogenic mutations in guanine nucleotide-binding proteins of human adreno-cortical neoplasms. J Clin Endocrinol Metab. 1993;77:1419-22.
57. Reincke M. Mutations in adreno-cortical tumors. Horm Metab Res. 1998; 30:447-55.
58. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhy RG. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab. 1997;82:3570-3.
59. Ogishima T, Shibata H, Shimada H, Mltani F, Suzuki H, Saruta T, et al. Aldosterone synthase cytochrome P-450 expressed in the adrenals of patients with primary aldosteronism. J Biol Chem. 1991;266:10731-4.
60. Sachse R, Shao XJ, Rico A, Finckh U, Rolfs A, Reincke M, et al. Absence of angiotensin II type 1 receptor gene mutations in human adrenal tumors. Eur J Endocrinol. 1997;137:262-6.
61. Boston BA, Mandel S, LaFranchi S, Bliziotes M. Activating mutation in the stimulatory guanine nucleotide-binding protein in an infant with Cushing's syndrome and nodular adrenal hyperplasia. J Clin Endocrinol Metab. 1994;79:890-3.
62. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, et al. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355: 262-5.
63. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism. Endocrinol Metab Clin North Am. 1994;23:285-97.
64. Torpy D, Stratakis CA, Chrousos GP. Hyper-and hypo-aldosteronism. Vitam Horm. 1999;46:177-216.
65. Taymans SE, Pack S, Pak E, Torpy DJ, Zhuang Z, Stratakis CA. Human CYP11B2 (aldosterone synthase) maps to chromosome 8q24.3. J Clin Endocrinol Metab. 1998;83:1033-6.
66. Torpy DJ, Gordon RD, Lin JP, Huggard PR, Taymans SE, Stowasser M, et al. Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene. J Clin Endocrinol Metab. 1998;83:3214-8.
67. Gordon RD. Primary aldosteronism: a new understanding. Clin Exp Hypertens. 1997;19:857-70.
68. Henry I, Grandjouan S, Couillin P, Barichard F, Huerre-Jeanpierre C, Glaser T, et al. Tumor-specific loss of 11p15.5 alleles in del11p13 Wilms tumor and in familial adrenocortical carcinoma. Proc Natl Acad Sci USA. 1989;86:3247-51.
69. Beckers A, Abs R, Willems P. Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): toss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus. J Clin Endocrinol Metab. 1992;75:564-70.
70. Stratakis CA, Kirschner LS. Clinical and genetic analysis of primary bilateral adrenal diseases (micro-and macronodular disease) leading to Cushing syndrome. Norm Metab Res. 1998;30:456-63.
71. Yano T, Linehan M, Anglard P, Lerman MI, Daniel LN, Stein CA, et al. Genetic changes in human adrenocortical carcinomas. J Natl Cancer Inst. 1989;81:518-23.
72. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250:1233-8.
73. Lin SR, Lee YJ, Tsai JH. Mutations of the p53 gene in human functional adrenal neoplasms. J Clin Endocrinol Metab. 1994;78:483-91.
74. Liu J, Kahri AI, Heikkila P, Voutilainen R. Ribonucleic acid expression of the clustered imprinted genes, p57KIP2, insulin-growth factor II, and H19, in adrenal tumors and cultured adrenal cells. J Clin Endocrinol Metab. 1997; 82:1766-71.
75. Hatada I, Inazawa J, Abe T, Nakayama M, Kaneko Y, Jinno Y, et al. Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors. Hum Mol Genet. 1996;5:783-8.
76. Gicquel C Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, Schlumberger M, et al. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab. 1997;82: 2559-65.
77. Clouston WM, Cannell GC, Fryar BG, Searle JW, Martin NI, Mortimer RH. Virilizing adrenal adenoma in an adult with the Beckwith-Wiedemann syndrome: paradoxical response to dexamethasone. Clin Endocrinol (Oxf). 1989;31:467-73.
78. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 1997;150:1-13.
79. Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst. 1994;86:1707-10.
80. Sameshima Y, Tsunematsu Y, Watanabe S, Tsukamoto T, Kawa-ha K, Hirata Y, et al. Detection of novel germ-line p53 mutations in diverse-cancer-prone families identified by selecting patients with childhood adrenocortical carcinoma. J Natl Cancer Inst. 1992;82:703-7.
81. Reincke M, Karl M, Travis WH, Mastorakos G, Allolio B, Linehan HM, et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J Clin Endocrinol Metab. 1994;78:790-4.
82. Figuereldo BC, Stratakis CA, Sandrini R, DeLacerda L, Pianovski MA, Giatzakis C, et al. Comparative genomic hybridization (CGH) analysis of adrenocortical tumors in childhood. J Clin Endocrinol Metab. 1999;84:1116-21.
83. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992;258:818-21.
84. du Manoir S, Speicher M, Joos S, Schrock E, Popp S, Dohner H, et al. Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet. 1993;90:590-610.
85. Kjellman M, Kallioniemi OP, Karhu R, Hoog A, Farnebo LO, Auer G, et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. Cancer Res. 1996;56:4219-23.
86. Stratakis CA, Carney JA, Lin JP, Papanicolaou DA, Karl M, Kastner DL, et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest. 1996;97:599-607.
87. Casey M, Mah C, Merliss AD, Kirschner LS, Taymans SE, Denio AE, et al. Identification of a novel genetic locus for familial cardiac myxomas and Carney complex. Circulation. 1998;98:2560-6.
88. Torpy DJ, Stratakis CA, Gordon RD. Linkage analysis of familial hyperaldosteronism type II - absence of linkage to the gene encoding the angiotensin II receptor type I [Letter]. J Clin Endocrinol Metab. 1998;83:1046.
89. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science. 1997;276:404-7.
90. Skogseid B, Rastad J, Gobl A, Larsson C, Backlin K, Juhlin C, et al. Adrenal lesion in multiple endocrine neoplasia type 1. Surgery. 1995;118: 1077-82.
91. Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998;129:484-94.
92. Wenig BM, Heffess CS, Adair CF. Atlas of Endocrine Pathology. Philadelphia: WB Saunders; 1997:272-87.
93. Angeli A, Osella G, Ali A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemidogical data from the National Italian Study Group. Horm Res. 1997;47:279-83.
94. Kasperlik-Zaluska AA, Roslonowska E, Slowinska-Srzednicka J, Migdalska B, Jeske W, Makowska A, et al. Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf). 1997;46:29-37.
95. Barzon L, Scaroni C, Sonino N, Fallo F, Gregianin M, Macri C, et al. Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. J Clin Endocrinol Metab. 1998;83:55-62.
96. Terzolo M, Ali A, Osella G, Mazza E. Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici. Arch Surg. 1997;132:914-9.
97. Mantero F, Masini AM, Opocher G, Giovagnetti M, Arnaldi G. Adrenal incidentaloma: an overview of hormonal data from the National Italian Study Group. Horm Res. 1997;47:284-9.
98. Bondanelli M, Campo M, Trasforini G, Ambrosio MR, Zatelli MC, Franceschetti P, et al. Evaluation of hormonal function in a series of incidentally discovered adrenal masses. Metabolism. 1997;46:107-13.
99. Streeten DH, Tomycz N, Anderson GH. Reliability of screening methods for the diagnosis of primary aldosteronism. Am J Med. 1979;67:403-13.
100. Lipsett MB, Hertz R, Ross GT. Clinical and pathophysiologic aspects of adrenocortical carcinoma. Am J Med. 1963;35:374.
101. Conn JW. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955;45:3-17.
102. Biglieri EG. Primary aldosteronism. Curr Ther Endocrinol Metab. 1997;6: 170-2.
103. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED Jr, Sos TA, Atlas SA, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med. 1994;121:877-85.
104. Melby JC. Diagnosis of hyperaldosteronism. Endocrinol Metab Clin North Am. 1991;20:247-55.
105. Kruger C, Rauh M, Dorr HG. Immunoreactive renin concentrations in healthy children from birth to adolescence. Clin Chim Acta. 1998;274:15-27.
106. Kaplan NM. Endocrine hypertension. In: Wilson JD, Foster DW, eds. Williams Textbook of Endocrinology. 8th ed. Philadelphia: WB Saunders; 1992: 707-31.
107. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol. 1994;21:315-8.
108. Ferriss JB, Beevers DG, Brown JJ, Davies DL, Fraser R, Lever AF, et al. Clinical, biochemical and pathological features of low-renin ('primary') hyperaldosteronism. Am Heart J. 1978;95:375-88.
109. Edwards CR. Primary mineralocorticoid excess syndromes. In: DeGroot LJ, ed. Endocrinology. 3d ed. Philadelphia: WB Saunders; 1995:1775-803.
110. Gordon RD. Primary aldosteronism. J Endocrinol Invest. 1995;18:495-511.
111. Young WF Jr, Klee GG. Primary aldosteronism. Diagnostic evaluation. Endocrinol Metab Clin North Am. 1988;17:367-95.
112. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD. A new genetic test lot familial hyperaldosteronism type 1 aids in the detection of curable hypertension. Biochem Biophys Res Commun. 1995;207:565-71.
113. Meier CA, Biller BM. Clinical and biochemical evaluation of Cushing's syndrome. Endocrinol Metab Clin North Am. 1997;26:741-62.
114. Chrousos GP, Schuermeyer T. Doppman J. Oldfield EH, Schulte HM, Gold PW, et al. NIH conference. Clinical applications of corticotropin-releasing factor. Ann Intern Med. 1985;102:344-58.
115. Flack M, Chrousos GP. Neoplasms of the adrenal cortex. In: Holland JF, Bust RF, Morton DL, Frei El, Kufe DW, Weischelbaum RK, eds. Cancer Medicine. 4th ed. Baltimore: Williams & Wilkins; 1996:1563-70.
116. Mendonca BB, Lucon AM, Menezes CA, Saldanha LB, Latronico AC, Zerbini C, et al. Clinical, hormonal and pathological findings in a comparative study of adrenal cortical neoplasms in childhood and adulthood. J Urol. 1995;154:2004-9.
117. Freeman D. Steroid hormone-producing tumors in man. Endocr Rev. 1978; 7:204-20.
118. Crapo L. Cushing's syndrome: a review of diagnostic tests. Metabolism. 1979;28:955-77.
119. Kaye TB, Crapo L. The Cushing syndrome: an update of diagnostic tests. Ann Intern Med. 1990;112:434-44.
120. Nieman LK, Oldfield EH, Wesley R, Chrousos GP, Loriaux DL, Cutler GB Jr. A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab. 1993;77:1308-12.
121. Orth DN. Cushing's syndrome. N Engl J Med. 1995;332:791-803.
122. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990;322:1195-201.
123. Herrera MF, Grant CS, van Heerden JA, Sheedy PF, Ilstrup DM. Incidentally discovered adrenal tumors: an institutional perspective. Surgery. 1991;110:1014-21.
124. Lenders JW, Keiser HR, Goldstein DS, Willemsen JJ, Friberg P, Jacobs MC, et al. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med. 1995;123:101-9.
125. Doppman JL. Problems in endocrinologic imaging. Endocrinol Metab Clin North Am. 1997;26:973-91.
126. Korobkin M. Overview of adrenal imagine/adrenal CT. Urol Radiol. 1989; 11:221-6.
127. Dunnick NR. Hanson lecture. Adrenal imaging: current status. AJR Am J Roentgenol. 1990;154:927-36.
128. Shapiro B, Fig LM, Gross MD, Khafagi F. Contributions of nuclear endocrinology to the diagnosis of adrenal tumors. Recent Results Cancer Res. 1990;118:113-38.
129. Korobkin M, Lombardi TJ, Aisen AM, Francis IR, Quint LE, Dunnick NR, et al. Characterization of adrenal masses with chemical shift and gadolinium-enhanced MR imaging. Radiology. 1995;197:411-8.
130. Cutwater EK, Siegelman ES, Radecki PD, Piccoli CW, Mitchell DG. Distinction between benign and malignant adrenal masses: value of T1-weighted chemical-shift MR imaging. AJR Am J Roentgenol. 1995;165:579-83.
131. Barzilay JI, Pazianos AG. Adrenocortical carcinoma. Urol Clin North Am. 1989;16:457-68.
132. Young WF Jr. Pheochromocytoma and primary aldosteronism: diagnostic approaches. Endocrinol Metab Clin North Am. 1997;26:801-27.
133. Doppman JL, Gill JR Jr. Hyperaldosteronism: sampling the adrenal veins. Radiology. 1996;198:309-12.
134. Schteingart D. Treating adrenal cancer. Endocrinologist. 1992;2:149-57.
135. Chee C Ravinthiran T, Cheng C Laparoscopic adrenalectomy: experience with transabdominal and retroperitoneal approaches. Urology. 1998;51:29-32.
136. Hansen P, Bax T. Swanstrom L. Laparoscopic adrenalectomy: history, indications, and current techniques for a minimally invasive approach to adrenal pathology. Endoscopy. 1997;29:309-14.
137. Korman JE, Ho T, Hiatt JR, Phillips EH. Comparison of laparoscopic and open adrenalectomy. Am Surg. 1997;63:908-12.
138. Miyake O, Yoshimura K, Yoshioka T, Honda M, Kokado Y, Miki T, et al. Laparoscopic adrenalectomy. Comparison of the transperitoneal and retroperitoneal approach. Eur Urol. 1998;33:303-7.
139. Walz MK, Peitgen K, Sailer B, Giebler RM, Lederbogen S, Nimtz K, et al. Subtotal adrenalectomy by the posterior retroperitoneoscopic approach. World J Surg. 1998;22:621-6.
140. Gagner M, Pomp A, Heniford BT, Pharand D, Lacroix A. Laparoscopic adrenalectomy: lessons learned from 100 consecutive procedures. Ann Surg. 1997;226:238-46.
141. Schell SR, Talamini MA, Udelsman R. Laparoscopic adrenalectomy. Adv Surg. 1997;31:333-50.
142. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery. 1992;112:963-70.
143. Khorram-Manesh A, Ahlman H, Jansson S, Wangberg B, Nilsson O, Jakobsson CE, et al. Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg. 1998;22:605-11.